SSTR2 and growth hormone-producing pituitary gland neoplasm: This could be related to the lower SSTR2 expression at baseline in somatotropinomas resistant to SSAs, or because of feedback mechanisms of the GH–IGF-I axis and the downregulation of SSTR2 due to prior SSA treatment [46].